Bispecific antibodies a new hot rod on the anti-cancer circuit
Next-gen bispecific antibodies (BsAbs) are on the move. The blockbuster potential of the class has galvanized biopharma, with deals and assets racing to capture the pole position as the entire field gains speed.
DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck’s REVEAL Genetic Analysis
Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck’s latest analysis of anacetrapib in REVEAL.
ACC: Merck anacetrapib reveal bodes neutral at best for DalCor’s dalcetrapib
Pfizer, Roche, Lilly and finally, Merck. One by one, they ended their CETP inhibitor programs, giving up the ghost on a once-vaunted class of cholesterol-targeting drugs thought to be a potential game-changer for heart disease. In spite of the mass exodus, little DalCor Pharmaceuticals emerged in 2015, with the Roche castoff dalcetrapib and a goal to succeed where the heavy hitters of Big Pharma had failed.
Tulane working on new stroke drugs that tweak brain chemistry
“Drugs currently on the market to treat hypertension work on the blood vessels by either dilating them, reducing pressure in them by eliminating salt and water or slowing down the heart rate,” said Bruno Besse, M.D., medical director of the French biotech company Quantum Genomics, which developed the drug.
ProQR Therapeutics sets goals for 2023
ProQR Therapeutics, a company focused on treating rare diseases, announced plans to advance its pipeline of RNA medicines to treat inherited retinal diseases to include two fully approved commercial products in Europe and the U.S., three late-stage clinical therapies and seven early-stage therapies by 2023.
Oral Insulin Innovation
While clinical data suggest an oral insulin product may finally be within reach, the technology struggles to compete with injectables on price and efficacy. A handful of academics and companies are pushing preclinical innovation in formulation and device design, aiming to solve the commercial conundrum.
As the FDA warns against ‘young blood,’ an ambitious Silicon Valley startup tests a cocktail for Alzheimer’s
The executives at Alkahest have heard plenty of vampire jokes. They are, after all, turning to blood from young donors in search of an elixir for diseases associated with aging. And yes, they’re in Silicon Valley. But this five-year-old biotech company led by Genentech alums is doing serious science.
